CancerLinQ® Continues to Add Practices and Data; CancerLinQ Discovery™ Open for Queries

CancerLinQ® Continues to Add Practices and Data; CancerLinQ Discovery Open for Queries

The CancerLinQ® initiative continues to add strategic alliances and practices to the CancerLinQ platform. CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, has signed formal collaboration agreements with seven other nonprofit associations and two federal agencies: American Academy of PAs, American Society for Radiation Oncology, Cancer Informatics for Cancer Centers, College of American Pathologists, Drug Information Association, U.S. Food and Drug Administration, the Hematology/Oncology Pharmacy Association, National Cancer Institute, and the Oncology Nursing Society.

CancerLinQ is a platform containing growing amounts of real-world cancer information. This national initiative will allow cancer providers to improve the quality and value of their care by aggregating and analyzing cancer patient medical records and measuring their care against that of their peers and recommended guidelines.

At present, 110 practices in 40 states and the District of Columbia, representing thousands of oncologists, have signed agreements to participate in CancerLinQ. To learn more about participating in CancerLinQ, visit online.

CancerLinQ Discovery

Another product from CancerLinQ LLC, CancerLinQ Discovery, is now open for research proposals. CancerLinQ Discovery is comprised of sub-cohorts of anonymized and statistically de-identified clinical data from the CancerLinQ platform. Physicians, researchers, and analysts in the oncology field can request from the CancerLinQ Discovery Research & Publications Committee, the volunteer committee charged with reviewing and approving research requests using data from CancerLinQ Discovery, for use in creating new clinical knowledge and improving patient outcomes.

This platform is designed to further ASCO’s mission of improving patient outcomes and quality, with the long-term goal of helping the oncology community learn from the experiences of millions of patients with cancer to help optimize the care of each patient.

Anyone in the cancer community is offered access to distinct sets of aggregated, de-identified patient data with the purpose of investigating specific research questions. The requests will be reviewed by the CancerLinQ Discovery Research & Publications Committee. The CancerLinQ Discovery data access request involves two steps: Step one is downloading and completing the CancerLinQ Discovery Data Request Application. Step two requires applicants to fill out the CancerLinQ Discovery Data Request Form, which includes contact, demographic, and organizational information. Once the forms are complete and submitted, they will be screened to ensure the application materials are complete and the submitted request aligns with ASCO’s mission. To learn how to submit a request, go to our website.

CancerLinQ and CancerLinQ Discovery are products of CancerLinQ LLC. For more information, please visit us online.